DOCSLIB.ORG

Muhammad Zahid

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Muhammad Zahid Development of a Specific Enzyme Linked Immunosorbent Assay (ELISA) for the Detection of Fluoroquinolone Antibiotic Residues in Chicken Liver, Prawn and Milk Muhammad Zahid Thesis submitted in partial fulfilment of the requirement for the Degree of Master of Science (Research) School of Chemical Engineering The University of New South Wales April, 2011 ABSTRACT Extensive utilisation of fluoroquinolones (FQs) in agricultural and aquacultural practices leads to two major food safety issues: 1) the issues regarding the presence of FQs residues in food and 2) the development of FQs resistant bacteria in animals, which may be transferable to humans. This may have an implication to human health, in particular for the treatment of infection. This thesis describes the design and synthesis of novel haptens for (enrofloxacin) ENR, ciprofloxacin and norfloxacin, the production of specific antibodies, and the formatting and characterizing of an indirect competitive Enzyme‐Linked ImmunoSorbent Assay (ELISA) for detection of ENR. The design and synthesis of FQs haptens involved the following approaches: 1) synthesising ENR hapten by attaching a tert‐butyl linker on a carboxylic group, and 2) synthesising ciprofloxacin and norfloxacin haptens by attaching a 4‐ bromobutane NHS ester and bromocrotyl NHS ester linkers respectively on the piperazinyl moiety. Highly specific polyclonal antibodies were generated against the ENR‐Keyhole Limpet Haemocyanine (KLH) conjugate. The optimized ELISA exhibited higher sensitivity in a homologous assay than a heterologous assay, suggesting the developed antibody was ‐1 extremely specific to ENR. The ELISA displayed an IC50 value of 11.7 µg L ± 1.7 with a limit of detection (LOD) value of 2.4 µg L‐1 ± 0.4. High specificity of the developed assay was evidenced by low cross‐reactivity to seven structurally related FQs compounds (danofloxacin, enofloxacin, sarafloxacin, perfloxacin, nalidixic acid, ciprofloxacin and norfloxacin). The effects of surfactants (Tween 20), water miscible organic solvent (methanol, ethanol, acetonitrile, and acetone) and pH conditions (5.5‐9.5) were also evaluated. Briefly, Tween 20 affected considerably on colour development, but not the assay sensitivity. Of the solvents tested, up to 5% methanol showed no significant effects on the assay sensitivity. The sample preparation were also optimized for milk, chicken liver and prawn, yielding the recoveries between 64 (± 3) and 125 (± 8)%. This ELISA will be particularly useful for screening ENR residues in animal and marine derived products to improve antibiotic safety in developing countries such as Indonesia. i ACKNOWLEDGEMENTS “In the name of ALLAH, the most gracious and merciful” First and foremost I would like to express my sincerest gratitude to ALLAH SWT, my Lord and Cherisher, for guiding and blessing in every single step of my life. Indeed, without his help and will, nothing is accomplished. I am heartily thankful to my supervisor, Dr. Nanju Alice Lee, whose encouragement, guidance and support from the very early to the final stage of this research, enabled me to develop an understanding of the subject as well as gave me extraordinary experiences throughout the work. Her encouragement has triggered and nourished my intellectual maturity that I will benefit from. I am grateful in every possible way and hope to keep up our collaboration in the future. I gratefully acknowledge my co‐supervisor, A/Prof. Naresh Kumar for his advice, expertise, and supervision. It has been an honour to have had the opportunity to work in his laboratory. I also would like to express my gratitude to Dr. George Iskander for his involvement, ideas, research passion and crucial contribution has made him one of the backbones of this research. Many thanks go to Dr. Victor Wong for the precious time rendered in proofreading this thesis, including the critical comments and scientific ideas forwarded. I would like to thank Camillo Toraborelli for his technical assistance in the laboratory and his kindness in putting every requested chemical on my bench. Special thanks also to all fellow researchers in the Food Science and Nutrition Research laboratory, School of Chemical Engineering; Eriyanto Yusnawan, Maria Veronica Hoie, Karrie Kam, Yang Lu, Kim‐Yen Phan‐Thien, Ebtihal Khodijah, Chatchaporn Uraipong and Norma Karim, as well as those who are affiliated with, the Organic Chemistry laboratory, School of Chemistry; Samuel Kutty, Hakan Kandemir, Kitty Ho, Ren Chen, Rick Zhang, Raymond Chen, Adeline Lukmantara and Asep Kurnia Permana, for their support, knowledge, sharing, laughs, and even tears. I am so grateful to have you guys who are always around. You are such wonderful people and always make our laboratory such an incredible place to be. ii For financial assistance, I would like to express my deepest gratitude to AusAID through Australian Development Scholarship (ADS) for giving me a great opportunity to study at The University of New South Wales, Australia. Without this support, this research project would have been impossible. I would like to record my gratitude to the Indonesian government, and more specifically, The National Veterinary Drug Assay Laboratory, The Ministry of Agriculture of Republic of Indonesia, for allowing me to improve my skills and knowledge through this research project in Australia. This research project would not have been possible without the support of numerous other people, so I offer my regards and blessings to all who supported me in any way for the duration of the project. Lastly, I would like to dedicate this thesis to my beloved families and especially for my beloved wife; Isnindar, my little angel; Maura Thalita Chairinniswa, for their prayers, patience, understanding and endless love, throughout the duration of my studies. iii ABBREVIATIONS Ab‐ENR1 polyclonal antibody of ENR Amax maximum absorbance APCI atmospheric pressure chemical ionization BSA bovine serum albumin cBSA cationised‐bovine serum albumin CBT checkerboard titration CDCl3 deuterated chloroform CIP ciprofloxacin a conjugate of ciprofloxacin N‐hydroxysuccinimide ester and CIP1‐OA ovalbumin a conjugate of ciprofloxacin butyl N‐hydroxysuccinimide ester and CIP2‐OA ovalbumin 1‐cyclohexyl‐3‐(2‐morphplinyl‐4‐ethyl) carbodiimide methyl p‐ CMC toluene sulfonate CNS central nervous system CV coefficient of variation D2O deuterium oxide DAD diode array detection DAN danofloxacin DCC dicyclohexylcarbodiimide DCM dichloromethane DEPT distortionless enhancement by polarization transfer DIC diisopropylcarbodiimide DMAP 4‐dimethylaminopyridine DMF dimethylformamide DMSO dimethylsulfoxide DNA deoxyribonucleic acid EDC 1‐ethyl‐3‐(3‐dimethyl‐aminopropyl) carbodiimide hydrochloride iv ELISA enzyme linked immunosorbent assay ENO enoxacin ENR enrofloxacin a conjugate of ENR N‐hydroxysuccinimide ester and keyhole limpet ENR1‐KLH haemocyanin ENR1‐OA a conjugate of ENR N‐hydroxysuccinimide ester and ovalbumin ENR2‐OA conjugate of ENR acid and keyhole limpet haemocyanin ESI electrospray ionization EtOH ethanol EU European Union FAO/WHO Food and Agriculture Organisation/World Health Organisation FCL full cream liquid milk FCP full cream milk powder FG fish gelatine FLD fluorescence detection FLU flumequine FQs fluoroquinolones FSANZ Food Standard Australia New Zealand GAT gatifloxacin GC/MS gas chromatography/mass spectrometry GI gastrointestinal HAS human albumin serum HPLC high performance liquid chromatography HRMS high resolution mass spectrometry HRP horseradish peroxidise IBCF isobutylchloroformate Ig immunoglobulin IgG immunoglobulin g JEFCA joint expert committee on food additives v KLH keyhole limpet haemocyanin LC/MS liquid chromatography mass spectrometry LC/MS‐MS liquid chromatography/tandem mass spectrometry LOD limit of detection LOQ limit of quantification LRMS low resolution mass spectrometry Lv1 chicken liver from an organic source Lv2 chicken liver from Coles supermarket Lv3 chicken liver from butcher MAb monoclonal antibody MAR marbofloxacin MeOH methanol MRLs maximum residue limits NaH sodium hydride NAL nalidixic acid NAL‐OA a conjugate of nalidixic acid and ovalbumin NHS N‐hydroxysuccinimide NMR nuclear magnetic resonance NOR norfloxacin NOR‐OA a conjugate of norfloxacin and ovalbumin NSAID non steroid anti inflammatory drug OFL ofloxacin OA ovalbumin OXO oxolinic acid PAb polyclonal antibody PBS phosphate buffer saline PEF pefloxacin PEF‐OA a conjugate of pefloxacin ovalbumin vi Pr1 local prawn Pr2 Thai prawn Pr3 Malaysian prawn Rf retardation factor RO reverse osmosis SAR sarafloxacin SAR‐OA a conjugate of sarafloxacin and ovalbumin SARs structure activity relationships SD standard deviation SKL skim milk liquid SKP skim milk powder TEA triethylamine TFA tetrafluoroacetic acid TLC thin layer chromatography TMB 3,3’,5,5’‐tetramethylbenzidine USP the U.S. of pharmacopeia UV ultraviolet vii TABLE OF CONTENTS ABSTRACT ....................................................................................................... I ACKNOWLEDGEMENTS ..................................................................................... II ABBREVIATIONS ............................................................................................. IV LIST OF FIGURES ........................................................................................... XIII LIST OF TABLES ............................................................................................. XX CHAPTER 1. INTRODUCTION .............................................................................
Load more

Recommended publications
  • The Role of Nanobiosensors in Therapeutic Drug Monitoring
    Journal of Personalized Medicine Review Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring Vivian Garzón 1, Rosa-Helena Bustos 2 and Daniel G. Pinacho 2,* 1 PhD Biosciences Program, Universidad de La Sabana, Chía 140013, Colombia; [email protected] 2 Therapeutical Evidence Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia; [email protected] * Correspondence: [email protected]; Tel.: +57-1-8615555 (ext. 23309) Received: 21 August 2020; Accepted: 7 September 2020; Published: 25 September 2020 Abstract: Due to the high bacterial resistance to antibiotics (AB), it has become necessary to adjust the dose aimed at personalized medicine by means of therapeutic drug monitoring (TDM). TDM is a fundamental tool for measuring the concentration of drugs that have a limited or highly toxic dose in different body fluids, such as blood, plasma, serum, and urine, among others. Using different techniques that allow for the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the drug, TDM can reduce the risks inherent in treatment. Among these techniques, nanotechnology focused on biosensors, which are relevant due to their versatility, sensitivity, specificity, and low cost. They provide results in real time, using an element for biological recognition coupled to a signal transducer. This review describes recent advances in the quantification of AB using biosensors with a focus on TDM as a fundamental aspect of personalized medicine. Keywords: biosensors; therapeutic drug monitoring (TDM), antibiotic; personalized medicine 1. Introduction The discovery of antibiotics (AB) ushered in a new era of progress in controlling bacterial infections in human health, agriculture, and livestock [1] However, the use of AB has been challenged due to the appearance of multi-resistant bacteria (MDR), which have increased significantly in recent years due to AB mismanagement and have become a global public health problem [2].
    [Show full text]
  • A Review on the Current Classification and Regulatory Provisions for Medicines in Drug & Cosmetic Act, in the Light of Present Day Context
    Section Pharmaindustry Commentary A Review on the Current Classification and Regulatory Provisions for Medicines in Drug & Cosmetic Act, in the light of Present Day Context Prashant Tandon1, Varun Gupta2, Ashish Ranjan3, Purav Gandhi4, Anand Kotiyal5, 3 Aastha Kapoor 3 1Founder ;2VP & Head Medical Affair; Manager Medical Affair; 5Drug Data Analyst Medical Affair, 1mg Technologies Private Limited, 4th Floor, Motorola Building, MG Road, Sector 14, Gurugram, Haryana, 122001. 4Founder, Remedy Social, C/602, Tulip Citadel, Shreyas Tekra, Ambawadi, Ahmedabad 380015, Gujarat. ABSTRACT______________________________________________________________ Background: Current classification of medicines in Conclusions: We have recommended a revised drug India under Drug and Cosmetic Act into Schedule G, classification system that is more comprehensive in coverage and H, H1, X is outdated, evolved through patchwork over eliminates the overlaps between classes. Moreover, considering the years and needs to be thoroughly updated. The the implementation challenges for such a drug classification primary aim of the scheduling system is to ensure system in the diverse and fragmented ecosystem in India, we appropriate access to medicines while balancing recommend a technology backed platform to help monitor the public health and safety. India is experiencing a rapid implementation. transition with the rising burden of chronic non- communicable diseases where regular access of Key words: Drug Classification System, Drug and Cosmetic Act affordable medicines is critical for chronic disease India, Digitization of Prescriptions, Drug Schedules in India, management to prevent complications. Methods: We Schedule H, Monitoring Drug Schedule System analyzed drugs commonly selling across India, Received: 01.09.17 | Accepted:16.09.17 through multiple information sources including 1mg drug database, PharmaTrac (AIOCD-AWACS), Corresponding Author inventory data from distributors and retailers, Dr.
    [Show full text]
  • List Item Withdrawal Assessment Report for Garenoxacin Mesylate
    European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 18 October 2007 Doc. Ref: EMEA/CHMP/363573/2007 WITHDRAWAL ASSESSMENT REPORT FOR Garenoxacin Mesylate (garenoxacin) EMEA/H/C/747 Day 120 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. This should be read in conjunction with th e "Question and Answer" document on the withdrawal of the application: the Assessment Report may not include all available information on the product if the CHMP assessment of the latest submitted information was still ongoing at the time of the withdrawal of the application. 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: [email protected] http://www.emea.europa.eu ©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged TABLE OF CONTENTS I. RECOMMENDATION ........................................................................................................... 3 II. EXECUTIVE SUMMARY...................................................................................................... 3 II.1 Problem statement............................................................................................. .. ..................... 3 II.2 About the product ............................................................................................. .. ..................... 4 II.3 The development programme/Compliance with
    [Show full text]
  • Clinically Isolated Chlamydia Trachomatis Strains
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUIY 1988, p. 1080-1081 Vol. 32, No. 7 0066-4804/88/071080-02$02.00/0 Copyright © 1988, American Society for Microbiology In Vitro Activities of T-3262, NY-198, Fleroxacin (AM-833; RO 23-6240), and Other New Quinolone Agents against Clinically Isolated Chlamydia trachomatis Strains HIROSHI MAEDA,* AKIRA FUJII, KATSUHISA NAKATA, SOICHI ARAKAWA, AND SADAO KAMIDONO Department of Urology, School of Medicine, Kobe University, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe-city, Japan Received 9 December 1987/Accepted 29 March 1988 The in vitro activities of three newly developed quinolone drugs (T-3262, NY-198, and fleroxacin [AM-833; RO 23-6240]) against 10 strains of clinically isolated Chiamydia trachomatis were assessed and compared with those of other quinolones and minocycline. T-3262 (MIC for 90% of isolates tested, 0.1 ,ug/ml) was the most active of the quinolones. The NY-198 and fleroxacin MICs for 90% of isolates were 3.13 and 62.5 ,ug/ml, respectively. Recently, it has become well known that Chlamydia 1-ml sample of suspension was seeded into flat-bottomed trachomatis is an important human pathogen. It is respon- tubes with glass cover slips and incubated at 37°C in 5% CO2 sible not only for trachoma but also for sexually transmitted for 24 h. The monolayer was inoculated with 103 inclusion- infections, including lymphogranuloma venereum. In forming units of C. trachomatis. The tubes were centrifuged women, it causes cervicitis, endometritis, and salpingitis at 2,000 x g at 25°C for 45 min and left undisturbed at room asymptomatically (19), while in men it causes nongono- temperature for 2 h.
    [Show full text]
  • Nigerian Veterinary Journal 39(3)
    Nigerian Veterinary Journal 39(3). 2018 Asambe et al. NIGERIAN VETERINARY JOURNAL ISSN 0331-3026 Nig. Vet. J., September 2018 Vol 39 (3): 199 -208. https://dx.doi.org/10.4314/nvj.v39i3.3 ORIGINAL ARTICLE In Vitro Comparative Activity of Ciprofloxacin and Enrofloxacin against Clinical Isolates from Chickens in Benue State, Nigeria Asambe, A.1*; Babashani, M2. and Salisu, U. S.1 ¹.Federal University Dutsinma, Katsina State. 2.Ahmadu Bello University Zaria. *Corresponding author: Email: [email protected]; Tel No:+2348063103254 SUMMARY This study compares the in vitro activities of enrofloxacin and its main metabolite ciprofloxacin against clinical Escherichia coli and non-lactose fermenting enterobacteria isolates from chickens. Ten (10) Escherichia coli and 8 non lactose fermenting enterobacteriaceae species isolated from a pool of clinical cases at the Microbiology Laboratory of the Veterinary Teaching Hospital, University of Agriculture Makurdi were used in this study. Ten-fold serial dilution of 10 varying concentrations (0.1-50μg/mL) of enrofloxacin and ciprofloxacin were tested against the isolates in vitro by Bauer’s disc-diffusion method to determine and compare their antimicrobial activities against the isolates. The 18 isolates tested were susceptible to both enrofloxacin and ciprofloxacin, and their mean values in the susceptibility of Escherichia coli and non-lactose fermenters were significantly different (p < 0.01). The study concluded that the clinical isolates are susceptible to both enrofloxacin and ciprofloxacin though ciprofloxacin exhibit higher activity. Comparatively, ciprofloxacin was found to be more potent than enrofloxacin and the difference statistically significant. Ciprofloxacin was recommended as a better choice in the treatment of bacterial infections of chicken in this area compared to enrofloxacin.
    [Show full text]
  • A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sebastien Lefebvre
    A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sebastien Lefebvre To cite this version: Tessa Trouchon, Sebastien Lefebvre. A Review of Enrofloxacin for Veterinary Use. Open Journal of Veterinary Medicine, 2016, 6 (2), pp.40-58. 10.4236/ojvm.2016.62006. hal-01503397 HAL Id: hal-01503397 https://hal.archives-ouvertes.fr/hal-01503397 Submitted on 7 Apr 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - NoDerivatives| 4.0 International License Open Journal of Veterinary Medicine, 2016, 6, 40-58 Published Online February 2016 in SciRes. http://www.scirp.org/journal/ojvm http://dx.doi.org/10.4236/ojvm.2016.62006 A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sébastien Lefebvre USC 1233 INRA-Vetagro Sup, Veterinary School of Lyon, Marcy l’Etoile, France Received 12 January 2016; accepted 21 February 2016; published 26 February 2016 Copyright © 2016 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract This review outlines the current knowledge on the use of enrofloxacin in veterinary medicine from biochemical mechanisms to the use in the field conditions and even resistance and ecotoxic- ity.
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]
  • Fluoroquinolones for Treating Tuberculosis (Presumed Drug- Sensitive) (Review)
    Fluoroquinolones for treating tuberculosis (presumed drug- sensitive) (Review) Ziganshina LE, Titarenko AF, Davies GR This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2013, Issue 6 http://www.thecochranelibrary.com Fluoroquinolones for treating tuberculosis (presumed drug-sensitive) (Review) Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 3 BACKGROUND .................................... 5 OBJECTIVES ..................................... 6 METHODS ...................................... 6 RESULTS....................................... 9 Figure1. ..................................... 10 Figure2. ..................................... 12 ADDITIONALSUMMARYOFFINDINGS . 15 DISCUSSION ..................................... 20 Figure3. ..................................... 20 Figure4. ..................................... 21 AUTHORS’CONCLUSIONS . 23 ACKNOWLEDGEMENTS . 23 REFERENCES ..................................... 24 CHARACTERISTICSOFSTUDIES . 30 DATAANDANALYSES. 60 Analysis 1.1. Comparison 1 Fluoroquinolones plus standard regimen (HRZE) versus standard regimen alone (HRZE), Outcome1Deathfromanycause. 61 Analysis 1.2. Comparison 1 Fluoroquinolones plus standard regimen (HRZE) versus standard regimen alone (HRZE), Outcome2TB-relateddeath.
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]
  • An Investigation of Class 1 Integrons and Integrase Gene In
    AN INVESTIGATION OF CLASS 1 INTEGRONS AND INTEGRASE GENE IN ESCHERICHIA COLI AND MANNHEIMIA HAEMOLYTICA FROM BEEF CATTLE IN WESTERN CANADA A Thesis Presented to The Faculty of Graduate Studies of The University of Guelph by MATTHEW LESLIE In partial fulfillment of requirements for the degree of Master of Science May, 2011 © Matthew Leslie, 2011 Library and Archives Bibliotheque et 1*1 Canada Archives Canada Published Heritage Direction du Branch Patrimoine de I'edition 395 Wellington Street 395, rue Wellington OttawaONK1A0N4 Ottawa ON K1A 0N4 Canada Canada Your file Vote reference ISBN: 978-0-494-82791-8 Our We Notre r6f6rence ISBN: 978-0-494-82791-8 NOTICE: AVIS: The author has granted a non­ L'auteur a accorde une licence non exclusive exclusive license allowing Library and permettant a la Bibliotheque et Archives Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par I'lnternet, preter, telecommunication or on the Internet, distribuer et vendre des theses partout dans le loan, distribute and sell theses monde, a des fins commerciaies ou autres, sur worldwide, for commercial or non­ support microforme, papier, electronique et/ou commercial purposes, in microform, autres formats. paper, electronic and/or any other formats. The author retains copyright L'auteur conserve la propriete du droit d'auteur ownership and moral rights in this et des droits moraux qui protege cette these. Ni thesis. Neither the thesis nor la these ni des extraits substantiels de celle-ci substantial extracts from it may be ne doivent etre imprimes ou autrement printed or otherwise reproduced reproduits sans son autorisation.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Fluoroquinolones in the Management of Acute Lower Respiratory Infection
    Thorax 2000;55:83–85 83 Occasional review Thorax: first published as 10.1136/thorax.55.1.83 on 1 January 2000. Downloaded from The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults Peter J Moss, Roger G Finch Lower respiratory tract infections (LRTI) are ing for up to 40% of isolates in Spain19 and 33% the leading infectious cause of death in most in the United States.20 In England and Wales developed countries; community acquired the prevalence is lower; in the first quarter of pneumonia (CAP) and acute exacerbations of 1999 6.5% of blood/cerebrospinal fluid isolates chronic bronchitis (AECB) are responsible for were reported to the Public Health Laboratory the bulk of the adult morbidity. Until recently Service as showing intermediate sensitivity or quinolone antibiotics were not recommended resistance (D Livermore, personal communi- for the routine treatment of these infections.1–3 cation). Pneumococcal resistance to penicillin Neither ciprofloxacin nor ofloxacin have ad- is not specifically linked to quinolone resist- equate activity against Streptococcus pneumoniae ance and, in general, penicillin resistant in vitro, and life threatening invasive pneumo- pneumococci are sensitive to the newer coccal disease has been reported in patients fluoroquinolones.11 21 treated for respiratory tract infections with Resistance to ciprofloxacin develops rela- these drugs.4–6 The development of new fluoro- tively easily in both S pneumoniae and H influ- quinolone agents with increased activity enzae, requiring only a single mutation in the against Gram positive organisms, combined parC gene.22 23 Other quinolones such as with concerns about increasing microbial sparfloxacin and clinafloxacin require two resistance to â-lactam agents, has prompted a mutations in the parC and gyrA genes.11 23 re-evaluation of the use of quinolones in LRTI.
    [Show full text]